Kazia Therapeutics (KZIA) Debt to Equity (2011 - 2025)

Kazia Therapeutics (KZIA) posted Debt to Equity of -$0.38 for Q2 2025, up 41.32% on a QoQ basis from -$0.65 in Q2 2024, and up 41.32% year-over-year from -$0.27 in Q2 2024.

Kazia Therapeutics (KZIA) has 6 years of Debt to Equity data on file, last reported at -$0.38 in Q2 2025.

  • In Q2 2025, Debt to Equity rose 41.32% year-over-year to -$0.38; the TTM figure through Jun 2025 stood at -$0.38 (up 41.32% YoY), while the FY2025 annual figure was -$0.38, up 41.32% from the prior year.
  • Debt to Equity grew to -$0.38 in Q2 2025, from -$0.65 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.63 in Q4 2023 and bottomed at -$0.65 in Q2 2024.
  • A 4-year average of $0.24 and a median of -$0.1 in 2022 frame the typical range for Debt to Equity.
  • Annual changes were most pronounced in 2023 — Debt to Equity surged 808.34% — and 2024, when it tumbled 190.62%.
  • Year by year, Debt to Equity stood at -$0.1 in 2022, then surged by 1720.56% to $1.63 in 2023, then sank by 139.61% to -$0.65 in 2024, then jumped by 41.32% to -$0.38 in 2025.
  • The last three Debt to Equity figures came in at -$0.38 (Q2 2025), -$0.65 (Q2 2024), and $1.63 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt/Equity (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 0.06
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Kazia Therapeutics 1.55 Bn 1.55 Bn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2025 -0.38
Jun 30, 2024 -0.65
Dec 31, 2023 1.63
Jun 30, 2023 0.71
Jun 30, 2022 -0.10
Jun 30, 2018 0.00
Jun 30, 2011 0.24